SF3A2 and myelodysplastic syndrome: Cells treated with shRNA to suppress SF3A2 were found to differentially express 6061 genes with an adjusted p value < 0.05 as compared to the shLuc control, whereas only 807 genes were differentially expressed given the same threshold cutoff in the MDS patients with an SF3B1 mutations compared to those without (Figure 6E).